- Company
- TNBC treatment adds newly approved immunotherapy option
- by Eo, Yun-Ho Nov 30, 2020 06:21am
- Anticipation is heightening for the use of an immunotherapy Tecentriq (atezolizumab) in the triple-negative breast cancer (TNBC) treatment scene. Pharmaceutical industry sources reported Roche Korea’s PD-L1 inhibiting immunotherapy Tecentriq has recently successfully expanded the indication as a first-line treatment for TNBC, combined wi
- Company
- Can HPV vaccine for men be included in the NIP?
- by Eo, Yun-Ho Nov 30, 2020 06:21am
- It is worth paying attention to whether vaccinating men with HPV vaccine can be included in the National Immunization Program (NIP). Earlier this month, Hye-young Choi, a member of Democratic Party of Korea said that the human papillomavirus (HPV) vaccine NIP, which is currently being conducted only for 12-year-old girls, includes both men
- Company
- The market share of GLP-1 diabetes drug Trulicity is 99%
- by An, Kyung-Jin Nov 30, 2020 06:21am
- Trulicity, a diabetic treatment administered once a week, continues to dominate in the GLP-1 analog market. Despite the confusion of COVID-19 outbreak, it has set a new quarterly sales record, reaching &8361;40 billion in annual sales. It is leading the market expansion by recording a market share of over 99% with only a single item. Acco
- Company
- First generic release isn't related to original price cuts
- by Kim, Jin-Gu Nov 30, 2020 06:20am
- The Supreme Court of South Korea finally ruled that the company that launched First Generic due to the success of its patent strategy had no reason to be responsible for lowering the drug price of the original drug. The results of the Zyprexa (Olanzapine) lawsuit came out after 10 years. The result of this lawsuit received great attention
- Company
- Prevenar and Sky Cellflu soar, Keytruda tops again
- by Chon, Seung-Hyun Nov 30, 2020 06:20am
- The novel coronavirus infection (COVID-19) has shuffled the top pharmaceutical market leader board. While immunotherapy Keytruda topped the market again, the sales in a pneumococcal 13-valent conjugate vaccine Prevenar 13 and a flu vaccine Sky Cellflu 4 surged dramatically. The sales in innovative new drugs like Tagrisso and Prolia also grew not
- Company
- Beovu treating AMD passes the first gate to reimbursement
- by Eo, Yun-Ho Nov 26, 2020 06:05am
- A novel neovascular age-related Macular Degeneration (AMD) treatment Beovu (brolucizumab) has passed the first threshold to win the healthcare reimbursement in South Korea. The pharmaceutical industry sources reported the Health Insurance Review and Assessment Service (HIRA) Drug Reimbursement Evaluation Committee (DREC) recently green l
- Company
- Janssen's young man who saved her life after a hit & run
- by Eo, Yun-Ho Nov 26, 2020 06:04am
- "When I got my mind, I knew I was under the car. I was just shouting for help, but someone talked to me." At eleven o'clock on the night of February 17, Ji Hyun-Joo (48 yrs old) Korea Johnson & Johnson (J&J), general director of Consumer Health Care AP, returned to the company (LS Yongsan Tower) after a dinner in late winter, when it was
- Company
- Yuhan secured ₩230 billion in two years
- by Chon, Seung-Hyun Nov 25, 2020 06:24am
- Yuhan has secured about &8361;230 billion in new drug technology fees over the past two years. It has signed five technology transfer contracts, and has also collected milestones of more than &8361;100 billion in the development stage after technology export. Yuhan announced on the 24th that it will receive a staged technology fee (milesto
- Company
- HCP and patients waiting for new T-cell lymphoma option
- by won, jong-hyuk Nov 25, 2020 06:24am
- The performances of anticancer therapies are improving as time goes by. But some cancer types still use chemotherapy as a standard of care (SOC) developed in 1970s to this date, regardless of the technological advancement in the anticancer area. One of them is Peripheral T-Cell Lymphoma (PTCL). Typically, PTCL is one kind of non-Hodgkin lymph
- Company
- Atozet follow-on drugs conflicted over price manipulation
- by Chon, Seung-Hyun Nov 24, 2020 09:03am
- The South Korean dyslipidemia treatment Atozet market seems to be heating up with competition and conflict among consignment manufacturers. Companies in process of preparing for the Atozet generic have stated they would take a legal action against Chong Kun Dang’s violation of Fair Trade Act, claiming the Korean company is rigging the follow-on
